Piper Sandler analyst Adam Maeder downgraded Inspire Medical (INSP) to Neutral from Overweight with a price target of $55, down from $85.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSP:
- Inspire Medical Cuts 2026 Outlook Amid Reimbursement Headwinds
- Inspire Medical cuts FY26 adjusted EPS view to 75c-$1.25 from $1.85-$2.35
- Inspire Medical reports Q1 adjusted EPS 10c, consensus (26c)
- INSP Upcoming Earnings Report: What to Expect?
- Inspire Medical price target lowered to $64 from $70 at Truist